Clinical Trials Search
A Phase 1a/1b Trial of Trametinib in Combination with Sorafenib in Patients with Advanced Hepatocellular Cancer
The main purpose of this study is to see whether the combination of trametinib and sorafenib can help people with hepatocellular cancer. Researchers also want to find out if the combination of trametinib and sorafenib is safe and tolerable.
- To determine maximally tolerated dose of trametinib in combination with sorafenib in patients with hepatocellular cancer (HCC). - To explore and characterize the safety and tolerability of trametinib in combination with sorafenib at the maximum tolerated dose (MTD) established. - To explore the efficacy profile at the MTD established.